Cargando…
Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2–IIIB Cervical Cancer
Background: National Cancer Institute phase I #7336 and phase II #8327 clinical trials explored the safety and efficacy of triapine (NSC #663249) added to cisplatin radiochemotherapy in untreated patients with advanced-stage cervical cancer. Triapine inhibits ribonucleotide reductase, the rate-limit...
Autores principales: | Kunos, Charles A., Sherertz, Tracy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109518/ https://www.ncbi.nlm.nih.gov/pubmed/25105092 http://dx.doi.org/10.3389/fonc.2014.00184 |
Ejemplares similares
-
Triapine Radiochemotherapy in Advanced Stage Cervical Cancer
por: Kunos, Charles A., et al.
Publicado: (2018) -
Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers
por: Kunos, Charles A., et al.
Publicado: (2017) -
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers
por: Kunos, Charles A., et al.
Publicado: (2019) -
Survival Outcomes of Patients With Stage IB3 Cervical Cancer Who Undergo Abdominal Radical Hysterectomy Versus Radiochemotherapy
por: Li, Zhiqiang, et al.
Publicado: (2022) -
Lymphangiogenesis in cervical cancer evaluated by expression of the VEGF-C gene in clinical stage IB-IIIB
por: Franc, Magdalena, et al.
Publicado: (2015)